title: Study on correlation between PKIB and pAkt expression in breast cancer tissues.
abstract: This study is to explore the expression of cyclic AMP (cAMP) dependent protein kinase inhibitor (PKIB) in human breast cancer and the correlation with phosphorylated protein kinase B (pAkt) expression in the tumor tissues.
  
  
  
  Surgical removal of the tissue samples from 148 patients with primary breast cancer from 2011-2015 were selected, and then we detected the PKIB, estrogen receptor (ER), progesterone receptor (PR) and proto oncogene (HER2) by using immunohistochemical technique and the Allred score classification standard. The clinical pathological factors such as tumor diameter, lymph node metastasis and tumor stage, etc. were analyzed statistically. Then we detected that the PKIB and pAkt respectively of immunohistochemical expression and cellular localization of four subtypes in patients which were luminal A, luminal B, HER2+/ER-type and triple negative breast cancer type.
  
  
  
  Immunohistochemistry staining showed when pAkt was positive and there were significant correlations with the expression of PKIB (p<0.05). Both positive staining reactions occurred in the cytoplasm of the tumor. Histopathological type, tumor diameter, lymph node metastasis, tumor stage and other clinical pathological factors were not significantly associated with the expression of PKIB. In addition, the expression of PKIB was also significantly associated with the triple negative breast cancer in the four subtypes (p<0.05).
  
  
  
  The expression of PKIB in the cytoplasm of tumor is closely related to pAkt and the triple negative breast cancer. It was concluded that the PKIB promoted the occurrence and development of breast tumors by regulating the Akt signaling pathway. PKIB will be a potential therapeutic target for breast cancer, especially in the diagnosis and treatment of triple negative breast cancer.
authors.affiliation: Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Cancer Hospital, Zhengzhou, Henan, China. s65489631jitu@163.com.
authors.forename: J-B
authors.initials: JB
authors.lastname: Zhang
authors.forename: W
authors.initials: W
authors.lastname: Song
authors.forename: Y-Y
authors.initials: YY
authors.lastname: Wang
authors.forename: M-G
authors.initials: MG
authors.lastname: Liu
authors.forename: M-M
authors.initials: MM
authors.lastname: Sun
authors.forename: H
authors.initials: H
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008875:Middle Aged; D000090063:Proto-Oncogene Mas; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D064726:Triple Negative Breast Neoplasms / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D047908:Intracellular Signaling Peptides and Proteins; D000090063:Proto-Oncogene Mas; D051057:Proto-Oncogene Proteins c-akt; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C000715470:MAS1 protein, human; C107591:PKIB protein, human; C508053:ERBB2 protein, human